Edition:
India

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

10.56USD
12 Aug 2020
Change (% chg)

$0.13 (+1.25%)
Prev Close
$10.43
Open
$10.58
Day's High
$10.59
Day's Low
$10.55
Volume
1,059
Avg. Vol
18,688
52-wk High
$11.82
52-wk Low
$4.99

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Announces New Drug Application For IV Tramadol Accepted For Review By FDA
Thursday, 13 Feb 2020 

Feb 13 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES NEW DRUG APPLICATION FOR IV TRAMADOL ACCEPTED FOR REVIEW BY FDA.AVENUE THERAPEUTICS INC - FDA SET A PRESCRIPTION DRUG USER FEE ACT ("PDUFA") GOAL ACTION DATE OF OCTOBER 10, 2020.  Full Article

Avenue Therapeutics Announces Submission Of New Drug Application For IV Tramadol
Wednesday, 11 Dec 2019 

Dec 11 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR IV TRAMADOL.AVENUE THERAPEUTICS INC - SUBMITTED NEW DRUG APPLICATION TO FDA FOR IV TRAMADOL.  Full Article

Avenue Therapeutics Reports Third Quarter 2019 Financial Results And Recent Corporate Highlights
Monday, 4 Nov 2019 

Nov 4 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.14.Q3 EARNINGS PER SHARE ESTIMATE $-0.28 -- REFINITIV IBES DATA.QTRLY CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $13.7 MILLION, COMPARED TO $15.5 MILLION AT JUNE 30, 2019.NET LOSS FOR THREE MONTHS ENDED SEPTEMBER 30, 2019 WAS $0.14 PER SHARE.AVENUE THERAPEUTICS- LOOKING AHEAD, ON TRACK TO SUBMIT A NEW DRUG APPLICATION FOR IV TRAMADOL TO U.S. FDA BY YEAR-END 2019.  Full Article

Avenue Therapeutics Q2 Loss Per Share $0.43
Wednesday, 14 Aug 2019 

Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.43.Q2 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.  Full Article

Avenue Therapeutics Q3 Loss Per Share $0.25
Thursday, 15 Nov 2018 

Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.25.  Full Article

BRIEF-Avenue Therapeutics Reports Q1 Loss Per Share Of $0.08

* AVENUE THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS